Bunavail is owned by Bdsi.
Bunavail contains Buprenorphine Hydrochloride; Naloxone Hydrochloride.
Bunavail has a total of 4 drug patents out of which 0 drug patents have expired.
Bunavail was authorised for market use on 06 June, 2014.
Bunavail is available in film;buccal dosage forms.
Bunavail can be used as treatment of opioid dependence, maintenance treatment of opioid dependence.
The generics of Bunavail are possible to be released after 24 April, 2035.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(4 years from now) | |
US8703177 | BDSI | Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
Aug, 2032
(9 years from now) | |
US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(12 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: Maintenance treatment of opioid dependence; Treatment of opioid dependence
Dosage: FILM;BUCCAL
40
United States
8
Japan
6
Australia
5
China
5
European Union
4
Brazil
4
Canada
3
Russia
3
New Zealand
3
Norway
3
Korea, Republic of
3
Hong Kong
3
Israel
2
Singapore
2
Spain
2
Mexico
2
EA
1
Croatia
1
South Africa
1
Cyprus
1
Slovenia
1
Hungary
1
Ukraine
1
Poland
1
RS
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic